One Cancer Start-Up’s Resolve To Crack The Mystery Of Metastasis

An Interview With Rgenix Co-Founders Masoud and Sohail Tavazoie

Rgenix, a New York-based start-up co-founded by three prominent physician researchers, is taking aim at what it contends is the future of cancer treatment:  finding drugs that shut off the biological chain reaction called tumor metastasis – the colonization of malignant cells throughout the body that ends up killing the majority of cancer patients.

Tavazoie_Masoud_1200
Masoud Tavazoie, CEO of Rgenix

In the fight against the seemingly random pathogenesis of cancer, one standout innovation is the ability to suppress the actions of specific genes that drive tumor progression in different cancers – the dreaded metastatic phase whose spread to other organs makes the disease a uniquely prolific killer. It is an unmet medical need of the highest order, yet most cancer research today centers on a rearguard mobilization of the immune system to find and destroy cancer receptors in individual tumors rather than address the underlying drivers of cancer growth and dispersion, across different malignancies. Yes, killing cancer cells in the tumor represents a step forward, but from the expectant eyes of the patient the ultimate test is death by metastatic disease – so shouldn’t preventing that lead the future of cancer research?

Three entrepreneurs determined to answer this question are Masoud, Sohail and Saeed Tavazoie, the sons of immigrants from Iran with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

MitoRx’s Muscle-Preserving Obesity Drug Takes Aim At GLP-1 Limitations

 
• By 

UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By 

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

More from In Vivo

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

MitoRx’s Muscle-Preserving Obesity Drug Takes Aim At GLP-1 Limitations

 
• By 

UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.